Efficacy of Argatroban in Critically Ill Patients with Heparin Resistance: A Retrospective Analysis

Abstract

The patients who do not respond even to very high dosages of heparin are assumed to suffer from heparin resistance. The aim of this study was to investigate whether critically ill patients suffering from heparin resistance generally have low antithrombin III (AT) levels, and if the direct thrombin inhibitor argatroban in that case can be an effective option to achieve prophylactic anticoagulation. The study was conducted at the Department for General and Surgical Intensive Care Medicine at the University Hospital Innsbruck. We retrospectively included all patients between 2008 and 2012, who received argatroban because of poor response to high-dosage heparin prophylaxis. The period under observation lasted in total for 9 days, 2 days of anticoagulation with unfractionated heparin (UFH) and 7 days with argatroban. The primary objective was to investigate if after 7 (± 1) hours of switching to argatroban the activated partial thromboplastin time (aPTT) levels were in a prophylactic range of 45 to 55 seconds. Further objectives were to assess the AT level, side effects such as bleeding or thromboembolism, platelet count, correlation between organ function and argatroban dose as well as any need for allogeneic blood products. The study population, consisting of 5 women and 15 men with a mean (± standard deviation, SD) age of 54.6 ± 16.3 years, differed in many clinical aspects. A median (interquartile range) heparin dose of 1,000, 819 to 1,125 IU/h was administered for 2 days and failed in providing a prophylactic anticoagulation measured by the aPTT. The mean aPTT level with heparin treatment was 38.5 seconds (± 4.7) its change within that period was not significant. After switching to argatroban, the mean increase of the aPTT levels in all study patients amounted from 38.5 to 48.3 seconds (p < 0.001). The rise in aPTT clearly reaches sufficient prophylactic anticoagulant levels. The maintenance of prophylactic aPTT levels was achieved over the period of 1 week. There was neither a correlation found between low-AT levels and occurrence of heparin resistance, nor between the simplified acute physiology score II and the administered argatroban dose (r = −0.224, p = 0.342). The results of the present study indicate that argatroban is an effective alternative therapy, especially in critically ill patients, to achieve prophylactic anticoagulation when heparin resistance occurs.

Keywords

heparin resistance - argatroban - prophylactic anticoagulation - thrombosis

• References

• 1 Fries D. Anticoagulation in critically ill patient [in German]. Wien Med Wochenschr 2009; 159 (19-20) 487-491
• 2 Dellinger RP, Levy MM, Rhodes A , et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39 (2) 165-228
• 3 Cook D, Douketis J, Crowther MA, Anderson DR ; VTE in the ICU Workshop Participants. The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20 (4) 314-319
• 4 Harris LM, Curl GR, Booth FV, Hassett Jr JM, Leney G, Ricotta JJ. Screening for asymptomatic deep vein thrombosis in surgical intensive care patients. J Vasc Surg 1997; 26 (5) 764-769
• 5 Joynt GM, Kew J, Gomersall CD, Leung VY, Liu EK. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest 2000; 117 (1) 178-183
• 6 Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997; 111 (3) 661-664
• 7 Anderson JA, Saenko EL. Heparin resistance. Br J Anaesth 2002; 88 (4) 467-469
• 8 Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance?. J Cardiothorac Vasc Anesth 2004; 18 (2) 129-130
• 9 Rodríguez-López JM, del Barrio E, Lozano FS, Muriel C. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?. Anesth Analg 2008; 107 (4) 1444-1445
• 10 Maurin N. Heparin resistance and antithrombin deficiency [in German]. Med Klin (Munich) 2009; 104 (6) 441-449
• 11 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67 (6) 639-643
• 12 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984; 57 (4) 585-596
• 13 Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53 (4) 691-695
• 14 Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009; 37 (1) 105-110
• 15 Yamada K, Tsuji H, Kimura S , et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res 2003; 109 (1) 55-64
• 16 Warkentin TE, Greinacher A, Koster A, Lincoff AM ; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 340S-380S
• 17 Alban S. Adverse effects of heparin. Handbook Exp Pharmacol 2012; (207) 211-263
• 18 Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care 2010; 14 (3) R90